Oncogenes can induce p53 through a signaling pathway involving p19/Arf. It was recently proposed that oncogenes can also induce DNA damage and this can induce p53 through the Atm DNA damage pathway. To assess the relative roles of Atm, Arf, and p53 in suppression of Rasdriven tumors we examined susceptibility to skin carcinogenesis in DMBA/TPA treated Atm and p53 deficient mice and compared these results to previous studies on Arf deficient mice. Mice with epidermal specific deletion of p53 showed increased papilloma number and progression to malignant invasive carcinomas compared to wild type littermates. In contrast, Atm deficient mice showed no increase in papilloma number, growth, or malignant progression. γ-H2AX and p53 levels were increased in both Atm+/+ and Atm-/-papillomas, while Arf-/-papillomas showed much lower p53 expression. Thus although there is evidence of DNA damage, signaling through Arf appears to regulate p53 in these Ras-driven tumors. In spontaneous and radiation induced lymphoma models, tumor latency was accelerated in Atm-/-p53-/-compound mutant mice compared to the single mutant Atm-/-or p53-/-mice, indicating cooperation between loss of Atm and loss of p53. Although p53 mediated apoptosis was impaired in irradiated Atm-/-lymphocytes, p53 loss was still selected for during lymphomagenesis in Atm-/-mice. In conclusion, in these models of oncogene or DNA damage induced tumors, p53 retains tumor suppressor activity in the absence of Atm. 
Introduction.
Carcinogenesis is an evolutionary process driven by mutation and selection 25 . In order to intervene in cancer development, it is important to understand the selective pressures which drive tumor evolution. The observation that p53 mutations are found at high frequency in most types of human cancers 18 indicates selection for cells which have disabled p53 is a nearly universal feature of cancer. p53 can be activated by numerous stressors including DNA damage, oncogene activation, abnormal cell adhesion, altered ribonucleotide pools, hypoxia, telomere erosion, and nutrient deprivation 15;48 . Activated p53 in turn, can suppress tumor development through the induction of cell cycle arrest, senescence, or apoptosis 48 . Of the many signals that have been reported to phosphorylate and activate p53, it is unclear which of these is physiologically relevant for tumor suppression in vivo. This is further complicated by variations between tissues and tumor etiology. DNA damage and activated oncogenes play direct causal roles in cancer induction and p53 activation and so both are reasonable candidates for generating selective pressure against p53 during tumor progression.
DNA damage is the best studied activator of p53. DNA double strand breaks (dsbs), which can be induced by ionizing radiation (IR) or other genotoxic agents, trigger a signaling cascade leading to p53-dependent cell cycle arrest or apoptosis. The protein kinase ATM, which is mutated in the inherited syndrome ataxia telangiectasia (AT), is a primary signal transducer for the cellular response to dsbs 43 . DNA dsbs activate ATM, which can directly phosphorylate p53 on Ser15 1;8 .
ATM also phosphorylates Chk2, which in turn phosphorylates p53 on Ser 20 9;42 . ATM impairs the activity of negative regulators of p53, including the ubiquitin ligases cop1 and mdm2 14;34 .
Collectively, these alterations lead to the rapid accumulation of p53 and activation of its 4 transcriptional functions, which, in turn, can trigger cellular responses such as cell cycle arrest or apoptosis.
AT patients carry homozygous mutations in ATM and have an increased risk of developing lymphoreticular malignancies 11 . Atm knockout mice are highly susceptible to lymphoid malignancies, but have not shown a marked predisposition to tumors in other tissues 3;50 Here we test the role of Atm during tumor evolution by comparing the effects of Atm and p53 loss in epithelial and lymphoid tumor models.
Results
We first tested the role of Atm in suppressing Ras-driven tumors by examining the susceptibility of Atm deficient mice to DMBA/TPA induced skin tumors. This protocol involves the topical application of the carcinogen DMBA to the dorsal skin, followed by twice weekly applications of the tumor promoter TPA. This induces benign squamous cell papillomas, a small percentage of which can progress to malignant squamous cell carcinomas after a long latency. Mutation of Hras is the initiating event in this tumor model and is detected in ~90% of both papillomas and carcinomas 39 .
Mutational inactivation of p53 occurs late and is strongly associated with papilloma to carcinoma conversion 7 . A causal role for p53 in malignant progression was established using germline p53 knockout mice, which showed a markedly accelerated rate of carcinoma formation 26 Figure 1D ), and some of these died before any reasonable chance of progression to carcinomas. Therefore we also analyzed the conversion frequency of papillomas to carcinomas for mice that lived at least 20 weeks post DMBA. In order to compare these results to the effects of p53 loss on skin tumor progression, we repeated the DMBA/TPA protocol on p53 deficient mice. We previously reported accelerated malignant progression in germline p53 deficient mice 26 and here we show similar effects with conditional p53 deficient mice (see Materials and Methods) 23 . The average number of papillomas was similar between Trp53 F2-10/F2-10 ; K14-Cre (skin-specific p53 deficient) mice compared to Trp53 Figure 1F ). In contrast, wild type littermates did not develop any carcinomas until after 30 weeks. This difference was highly significant (p=0.001). Thus, skinspecific p53 deletion markedly accelerates malignant skin tumor progression, a result similar to that seen in p53 germline nullizygous mice 24;26 . This establishes that the effect of p53 on inhibiting malignant progression is tumor cell autonomous. Both the Atm and p53 skin tumor studies were done using littermate wild type controls. This is important as the wild type mice from the two studies differed in carcinoma susceptibility, likely due to different genetic backgrounds (see Materials and Methods). Comparison between these two skin tumor studies reveals that p53 has a more significant impact on suppressing Ras-driven tumor progression than does Atm.
We next addressed if DNA damage signaling was prominent in papillomas and if this led to Atmdependent expression of p53. H2AX is rapidly phosphorylated in response to DNA double strand breaks 40 and phospho-H2AX (γ-H2AX) is widely used as a marker of DNA damage. However γ-H2AX also increases in M phase cells without DNA damage 21;35 and can be readily detected in epithelial cells during the hair cycle phase in untreated mouse skin 28 . Staining for γ-H2AX was seen in the occasional cell within the hair follicle of normal skin and in basal and suprabasal cells of the papillomas (Figure 2A ). Although Atm can phosphorylate H2AX after IR 44 we observed similar levels of γ-H2AX staining in papillomas from Atm+/+ and Atm-/-mice indicating there are kinases that can substitute for Atm to phosphorylate H2AX in vivo. Despite γ-H2AX staining, phospho-Chk2, a marker of DNA damage signaling, was low or undetectable in both Atm+/+ and Atm-/-papillomas ( Figure 2B ). As a positive control, staining for p-Chk2 was seen in irradiated intestinal crypts (data not shown). p53 was undetectable in normal skin but prominent in papillomas and primarily localized to keratinocytes within the basal layer ( Figure 2 ). Equivalent levels and cellular distribution patterns of p53 staining were seen in papillomas from Atm+/+ and Atm-/-mice. Expression of the p53 regulated gene p21 (Cdkn1a), and the Cdk inhibitor p16
(Ink4a), were also seen in both Atm+/+ and Atm-/-papillomas. As another measure of p53 functionality, we quantified proliferation and apoptosis. The mitotic index was similar in papillomas It is useful to compare these results to those seen in p19/Arf null mice. Arf is a tumor suppressor that induces p53 in response to oncogenic activation 36;41 . We previously showed accelerated papilloma to carcinoma progression in Arf deficient mice using an identical DMBA/TPA protocol 24 .
In comparison to papillomas from wild type and Atm null mice, Arf null papillomas showed reduced p53 expression and higher H2AX staining and increased mitotic activity ( Figure 2 ). This confirms our previous findings that Arf plays a critical role in the induction of p53 during benign tumor growth. Reduced p53 could explain the increased proliferation in these tumors and this may contribute to increased levels of H2AX. However the DNA damage p53 pathway is still functional in these tumors as irradiated tumor bearing Arf-/-mice showed robust p53 induction in papillomas 24 . These findings, together with the low levels of pChk2 in untreated papillomas, shows that the levels of DNA damage in untreated tumors may be insufficient to trigger a DNA damage response.
Thus tumor suppression by p53, at least in this model of epithelial cancer, is regulated by Arf and selection against p53 is driven by oncogenic signaling through Arf.
Compared to epidermal cells, Atm has a more critical role in regulating p53 in lymphoid cells 17 , so
we also examined the interaction of Atm and p53 in spontaneous and IR induced lymphoma models. The latency for spontaneous tumor development in Atm-/-mice (median age of death=116 days) was shorter than for p53-/-mice (median=141 days) ( Figure 3A ). Tumor latency was significantly accelerated in Atm-/-p53-/-compound mutant mice (median=84 days) relative to either single mutant alone, consistent with a previous study 49 . ~95% of Atm-/-and Atm-/-p53-/-mice developed CD3 positive T cell lymphomas, which presented as enlarged thymi, with 9 occasional splenic or lymph node involvement. The tumor spectrum differed slightly in the p53 nulls. 60% developed thymic lymphoma and 40% developed other tumor types, mainly sarcomas (Table 2) . Thus, the reduced tumor latency in Atm-/-p53-/-mice was mainly due to acceleration of T cell thymic lymphomas.
IR-induced p53 expression and apoptosis is markedly impaired in thymic lymphoid cells from adult Atm null mice 51 , indicating Atm plays a central role in regulating p53 and apoptosis in these cells.
We first verified that IR-induced apoptosis was impaired in thymocytes from young Atm deficient mice. Results shown in Figure 3C show reduced apoptosis in irradiated Atm-/-thymus compared to wild type littermates. If this Atm-dependent apoptotic pathway is critical for tumor suppression, a prediction is that germline Atm deficiency should effectively neutralize p53 in a radiation-induced tumor model. An additional cohort of mice was treated at two days of age with a single dose of 1.4
Gy. Neonatal radiation reduced latency to tumor development in p53-/-mice from a median of 141 days to 100 days ( Figure 3B ). However, radiation did not noticeably affect tumor development in Atm-/-mice. The median age to tumor development in irradiated Atm-/-mice was 113 days compared to 116 days in the non-irradiated cohort. Tumor latency in irradiated Atm-/-p53-/-compound mutants (median = 72 days) was again reduced compared to either single mutant alone. The predominant tumor type in all irradiated genotypes was CD3 positive T cell lymphomas, with a 95% incidence ( Table 2) .
We next asked if loss of Atm reduced or eliminated selection against p53 during tumor development by examining loss of heterozygosity (LOH) of p53 in tumors from Atm-/-p53+/-mice.
50% (4/8) of spontaneous thymic lymphomas and 89% (8/9) of IR-induced lymphomas from Atm-/-
p53+/-mice showed loss of the wild type p53 allele (Figure 4 ). This is comparable to 57% (4/7) loss of p53 in lymphomas from p53+/-mice ( Figure 4 ) and the range of 43-75% p53 LOH reported in previous studies 19;22;27;37 . Thus, p53 loss occurs in tumors with or without the presence of Atm.
Even under conditions where IR-induced p53-dependent apoptosis is disabled due to loss of Atm, selection against p53 remains. This indicates that although Atm regulates p53 dependent apoptosis in response to acute DNA damage, other Atm independent pathways influence the tumor suppressor function of p53, even in a tumor model where DNA damage was the inducing agent. This also implies that apoptosis is not the only mechanism of tumor suppression by p53.
Discussion
Here, we used three mouse models to compare the roles of Atm and p53 in suppression of oncogene and DNA damage induced tumor development. We first compared the effect of deletion That acute ionizing radiation was able to induce p53 in Arf null tumors 24 , shows that exogenous DNA damage can induce p53 in tumors in the absence of Arf. This further implies that the levels of endogenous DNA damage or damage induced signaling which is present in untreated tumors may be insufficient to activate p53.
The affects of Atm, Arf, and p53 on tumor progression were consistent with these signaling results.
Deletion of both p53 and Arf but not Atm markedly accelerated the progression of benign papillomas to invasive malignant carcinomas. In wild type mice, p53 loss is strongly selected for during progression of papillomas to carcinomas and p53 loss was less frequent in Arf null carcinomas. Together these results show that signaling through Arf induces p53 and this provides significant selective pressure against p53.
We also found that the latencies for both spontaneous and radiation-induced lymphomas were In summary, the requirement for Atm in regulating p53 in response to DNA damage varies between tissues and this may at least partially explain the tissue specific role of Atm in tumor suppression.
In the tumor models we examined, loss of Atm did not phenocopy the loss of p53; that is, p53 retained significant tumor suppressor activity in the absence of Atm. This highlights that there are multiple and in some cases redundant signals that can activate p53 during tumor suppression. In the case of Ras-driven skin tumors, Arf appears to play a more significant role than Atm in p53 regulation and tumor progression. Identifying the rate limiting steps in tumor progression in different tumor models and under different tumor etiologies remains an important goal in cancer research. In the broader picture, understanding the nature of the selective pressures that drive tumor evolution is a necessary step to designing effective, mechanistically-based interventions.
Materials and Methods:
Mice. F1 NIH/FVB;129 TRp53 F2-10/+ mice 23 were crossed to N1 NIH/C57 K14-Cre mice 47 and progeny intercrossed to generate experimental mice with the genotypes Trp53 papillomas stained for p53 were from a previous study 24 . Staining for all antibodies was done using a three step streptavidin technique. Sections were rehydrated and treated with high heat antigen retrieval using a 10mM citrate buffer (pH 6) and then stained with primary Ab. After staining with the primary antibody the sections were stained with a biotin conjugated secondary (Vector labs) followed by StreptABComplex/HRP (DAKO mice. The number of papillomas in p53 deficient mice at 23 and 25 weeks was greater then wild types (p= 0.003 and 0.04 respectively, using an unpaired t-test). F, Carcinoma free survival in DMBA/TPA treated p53 WT and skin specific p53 deleted mice (p53 conditional KO). The difference was highly significant (p= 0.001 using the log rank test). allele, mu= mutant p53 allele.
